Shopping Cart

Your shopping cart is currently empty

Selvigaltin

Name: Selvigaltin
Brand: TargetMol
SKU: T63751
Price: 278 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: GB1211) Copy Product Info

😃Good

Synonyms: GB1211

Catalog No. T63751 Copy Product Info

Purity: 99.49%

😃Good

Selvigaltin (GB1211) is an orally administered, highly selective small-molecule inhibitor of galectin-3 (Gal-3) with an IC₅₀ value of 12 nM in rabbits, exhibiting anticancer and anti-fibrotic activity. Selvigaltin reduces galectin-3 levels in the liver and decreases biomarkers of inflammation (cellular foci) and fibrosis (PSR, SHG), while simultaneously lowering the mRNA and protein expression of inflammatory and fibrotic biomarkers (IL-6, TGF-β3, SNAI2, collagen). Selvigaltin also restores T-cell activity and reduces tumor growth and metastasis. Selvigaltin is suitable for use in studies of liver fibrosis, non-alcoholic steatohepatitis (NASH), and tumors.

Cas No. 1978336-95-6

Pack Size	Price	USA Stock	Global Stock
1 mg	$278	In Stock	In Stock
5 mg	$689	In Stock	In Stock
10 mg	$1,180	In Stock	In Stock
25 mg	$2,380	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$826	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.49%

ee:100%

Appearance:Solid

Color:White

Resource Download

COA CSFC HNMR HPLC

Product Introduction

Selvigaltin AI Summary

Selvigaltin exhibits a diverse range of bioactivities, demonstrating significant pharmacokinetic and pharmacodynamic properties. The compound has a LogD of 3.0 according to shake-flask analysis, indicating moderate lipophilicity. It inhibits various CYP enzymes, including 2C19, 3A4, 1A2, 2C9, 2D6, 2C8, and 2B6, with inhibition constants greater than 10.0 μM, suggesting low potential for CYP-mediated drug-drug interactions at typical therapeutic concentrations. Additionally, Selvigaltin shows selective binding affinity to different Galectin proteins, indicating possible targeting specificity and potential therapeutic applications. Its permeability across human Caco-2 cells varies between apical to basolateral and basolateral to apical directions, highlighting its absorption characteristics. The compound exhibits variable stability in human and mouse hepatocytes with different clearance rates, and its clearance and oral bioavailability have been confirmed in C57BL/6 mice, providing essential pharmacokinetic insights. Moreover, it demonstrates plasma protein binding in both human and mouse plasma, affecting its distribution and free drug concentration. Selvigaltin inhibits the hERG channel at concentrations below 10.0 μM, indicating a need for cardiac safety assessment. It also displays binding affinity to the rat calcium L channel and the human dopamine transporter, with specific activity percentages, suggesting potential impacts on calcium signaling and neurotransmitter regulation..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Selvigaltin (GB1211) is an orally administered, highly selective small-molecule inhibitor of galectin-3 (Gal-3) with an IC₅₀ value of 12 nM in rabbits, exhibiting anticancer and anti-fibrotic activity. Selvigaltin reduces galectin-3 levels in the liver and decreases biomarkers of inflammation (cellular foci) and fibrosis (PSR, SHG), while simultaneously lowering the mRNA and protein expression of inflammatory and fibrotic biomarkers (IL-6, TGF-β3, SNAI2, collagen). Selvigaltin also restores T-cell activity and reduces tumor growth and metastasis. Selvigaltin is suitable for use in studies of liver fibrosis, non-alcoholic steatohepatitis (NASH), and tumors.
In vivo	Methods: Male New Zealand White rabbits were fed a high-fat diet (standard diet + 0.5% cholesterol + 2.5% vegetable oil) for 12 weeks. From week 9 to week 12 of HFD feeding, oral administration (0.3–30 mg/kg) was performed once daily (5 days per week) for 4 consecutive weeks. Results: Selvigaltin treatment significantly reduced galectin-3 protein and mRNA levels in the liver, confirming target binding.[1]
Synonyms	GB1211

Chemical Properties

Molecular Weight	533.32
Formula	C₁₉H₁₆BrF₃N₄O₄S
Cas No.	1978336-95-6
Smiles	[H][C@@]1([C@@H](O)[C@@H](CO)O[C@H](Sc2cncc(Br)c2)[C@@H]1O)n1cc(nn1)-c1cc(F)c(F)c(F)c1

Storage & Solubility Information

Storage

Keep away from direct sunlight,Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 265 mg/mL (496.89 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Corn Oil: 1 mg/mL (1.88 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8750 mL	9.3752 mL	18.7505 mL	93.7523 mL
5 mM	0.3750 mL	1.8750 mL	3.7501 mL	18.7505 mL
10 mM	0.1875 mL	0.9375 mL	1.8750 mL	9.3752 mL
20 mM	0.0938 mL	0.4688 mL	0.9375 mL	4.6876 mL
50 mM	0.0375 mL	0.1875 mL	0.3750 mL	1.8750 mL
100 mM	0.0188 mL	0.0938 mL	0.1875 mL	0.9375 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.